Isomorphic Labs: AI drug design company
Business milestones
- Jan 2024: AI drug discovery partnerships with Novartis and Eli Lilly
- Apr 2025: $600 million funding round led by Thrive Capital
- 2026 (expected): first AI-designed drugs enter clinical trials, according to Hassabis at Davos
Connection to mediKanren
Matt Might's MediKanren (a knowledge graph plus logical reasoning, used to repurpose existing drugs) is the manual forerunner of what Isomorphic Labs is doing at AI scale. The key difference is that Isomorphic designs new compounds from scratch at the molecular level rather than searching existing drug libraries.
Core technology
- Drug design engine
- Capability
Predicts small-molecule binding affinity faster, more cheaply and more accurately than traditional physics-based simulation
- Performance
2x the performance of AlphaFold 3
- Released
Feb 2026
- Foundation
AlphaFold (protein structure prediction), extended downstream into drug design
- Novel capability
Finds new binding pockets on proteins from the amino acid sequence alone, opening the way to entirely new drug targets
Founded
2021
Founder
Demis Hassabis (creator of AlphaFold and Nobel Prize co-winner)
Hassabis roadmap
- Step 1
Solve the chemistry problem: compound design, toxicity screening and prediction of safety properties. Timeline: 5-10 years to complete the Drug Design Engine.
- Step 2
Persuade regulators to accept AI predictions. Building regulatory trust will take about 10 or more AI-designed drugs going through the full pipeline. Possible future: skipping animal trials and speeding up dose trials.
Investment note
Private company, so not directly investable. Alphabet (GOOGL) is the parent and Isomorphic is a wholly owned subsidiary. Thrive Capital (Josh Kushner) is a major investor.
Parent
Alphabet (spun out of Google DeepMind)
Pipeline
- Projects
19
- Therapeutic areas
- oncology
- cardiovascular
- immunology
Vision quote
I want to literally cure cancer. I know people say that's the cliché, but what we're building at Isomorphic is general purpose.
A brief is a lead for our research, not a verified conclusion or advice.